Hepatitis Foundation International   photo
The Good We Do Living with Hepatitis News and Research Support Education Donate Contact Us Home

 

NNAC Online Learning Center Subscribe to Our Newsletter Parents

News and News Archive

Research Advances is located on the home page of our web site. We will continue to keep global NEWS posted to this site for reference. Please make sure that you are always referring to current information when making health care decisions or when educating others about hepatitis.

For more News and Features, see our homepage here.

Our News Archives can be viewed here.

Features Continued from Home Page...

Continued from Home Page...
HFI AWARDED $20,000 FROM ABBOTT FUND
Each year, more that 600,000 American become newly infected with viral hepatitis yet many of these cases go unreported. Often called the "silent epidemic", many individuals infected with viral hepatitis have not signs or symptoms of the disease until chronic infection or chronic liver disease has developed.  Education and outreach are key to combat these diseases that affect over 500 million people around the world.

"Often it is not the doctor, but a nurse or physician assistant that spends more time with a patient during an office visit", said Thelma King Thiel, Chairman and CEO, HFI. "That is why it is so important for HFI to offer our Foundation for Decision Making train-the-trainer programs which give health care providers advice on how to best educate patients about liver wellness and risky behaviors that could lead to a viral hepatitis infection."

Hepatitis literally means inflammation of the liver and is caused by infection with one of five viruses, hepatitis A, B, C, D, or E. Two of the most common infections are the hepatitis B virus (HBV) and the hepatitis C virus (HCV). Both infections can be transmitted from high-risk behaviors such as having sex with multiple partners or an infected person without a condom, or from sharing drugs, needles or drug paraphernalia when "shooting" drugs.

HFI seeks to raise awareness of viral hepatitis by educating the public and hepatitis patients about prevention, diagnosis and treatment of viral hepatitis. For more information about liver wellness or viral hepatitis, visit: www.hepatitisfoundation.org

Continued from Home Page...
SAMHSA GRANTEES APPLAUD LIVER WELLNESS APPROACH
Invited by Claudia Richards, Chief, HIV Behavioral Health Issues Branch, at the Center for Substance Abuse Prevention (CSAP), Thelma King Thiel, HFI’s CEO, addressed one hundred eighty of CSAP grant recipients at a two day conference in Washington DC, January 18th and 19th.  Making liver wellness "come alive" through humor and memorable analogies, Thiel had her audience's undivided attention.

I learned so much in just a few minutes,” commented Craig McGuire, M.S., a consultant conducting the evaluation of a SAMHSA project in Kentucky.

“Your upbeat approach is sorely needed to help our clients change their behaviors. We look forward to working with you,” said L. Elaine Sutton Mbionwu, CEO of The National Re-Entry Resource Center in Atlanta , GA.

Plans are already underway to provide HFI’s Foundation for Decision Making Training program for the Latin American Youth Center staff and constituents in Washington , DC .  The Orange Bar Foundation in California collaborated with HFI to address liver wellness and hepatitis in their program responsibilities. For more information about  HFI’s Training programs, call 800-891-0707

NEWS IN REVIEW

Australia's Therapeutic Goods Administration has taken a tough stance over the safety record of black cohosh, requiring that over the counter and alternative medicines containing the herbal must carry a warning for potential harm to the liver.  For more information, click here...

Anady's Pharmaceuticals, Inc. announced robust viral load reduction successfully achieved in Phase II clinical trial of ANA380 in Lamivudine-resistant hepatitis B patients.  For more information, click here...

A landmark study by F
lorida State University biologists could bolster the development of anti-viral therapy for hepatitis C by the discovery of the mechanism that inhibits HCV replication. For more information, click here...

Nabi Pharmaceuticals has received approval from the FDA to move its new Civacir product to a "fast track" status.  Civicar is an antibody designed to stop hepatitis C from re-infecting liver transplants.  For more information, click here...


2004/2005 News Archive                                                                  For a copy of News from 2004/2005, click here.

2006 News Archive
For a copy of News from 2006, click here.



Scroll to Top or Back to Home Page

 


the good we do  |  living with hepatitis  |  news & research  |  support donate  |  contact us  |  site map  |   home

nnac  |  online learning center  |  subscribe to our newsletter   |   disclaimer  |  privacy

 

 

Hepatitis Foundation International
(800) 891-0707
HFI@comcast.net

©2003. All rights reserved.